Highlight
– In ENLIGHTEN, ANK3-positive patients with treatment‑resistant depression (TRD) randomized to liafensine (1 or 2 mg daily) had a statistically and clinically significant greater reduction in MADRS score at day 42 than placebo (mean difference −4.4 points, 95% CI −7.6 to −1.3; P = .006).
– This is the first prospective, randomized, biomarker‑guided clinical trial in psychiatry reporting successful enrichment of responders using a genetic marker (ANK3).
